Pipeline

Registration No.
Drug name
Indication
Study
CTR20212848
Recombinant humanized monoclonal antibody against human epidermal growth factor receptor for injection conjugated a dolastatin derivative DUO5
Advanced solid tumors expressing HER2
An open, multicenter Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, immunogenicity, and initial antitumor activity of ZV0203 (ADC2122) in patients with advanced solid tumors expressing HER2